That’s a good point I bet it’s a priority for

That’s a good point I bet it’s a priority for this very reason. Out of all the data he spoke about that stuck out the most to me. Yet no mention of it on this most recent update is somewhat telling.

Why would he be so adamant and vocal that the data is urgent yet no mention of trials as of late? Cyrus himself in the past mentioned a trial in TNBC as a priority.

Money is the issue, of course unless we get a partner in that indication as well, which if I had to guess is a good possibility.

I guess my overall point is TNBC is far from dead just sounds like we may have to wait a little to see where this fits into the big picture.

Ohm if you read this. What’s your thoughts as to what could be so urgent about the actual data? My guess is maybe CTC almost completely stop growing and maybe huge reductions in metastasis. Maybe the overall survival data that we never got an update on will be in this publication?

All the sudden communication was cut completely short when we requested BTD on TNBC, that is if I’m remembering this correctly. We were all wondering how far free progression survival rate went out with CD07. I believe the excuse is we didn’t have that actual data past 12 months. Is that true still to this day?

https://www.biospace.com/article/releases/cyt...reviously/


I’ll try to add more information on this post as I find it about TNBC but I think I’m remembering this correctly.